Cargando…

Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells

BACKGROUND: Glucocorticoids (GCs) are often included in the therapy of lymphoid malignancies because they kill several types of malignant lymphoid cells. GCs activate the glucocorticoid receptor (GR), to regulate a complex genetic network, culminating in apoptosis. Normal lymphoblasts and many lymph...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Aaron L, Geng, Chuandong, Golovko, Georgiy, Sharma, Meenakshi, Schwartz, Jason R, Yan, Jiabin, Sowers, Lawrence, Widger, William R, Fofanov, Yuriy, Vedeckis, Wayne V, Thompson, E Brad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008436/
https://www.ncbi.nlm.nih.gov/pubmed/24795534
http://dx.doi.org/10.1186/1475-2867-14-35
_version_ 1782314449270472704
author Miller, Aaron L
Geng, Chuandong
Golovko, Georgiy
Sharma, Meenakshi
Schwartz, Jason R
Yan, Jiabin
Sowers, Lawrence
Widger, William R
Fofanov, Yuriy
Vedeckis, Wayne V
Thompson, E Brad
author_facet Miller, Aaron L
Geng, Chuandong
Golovko, Georgiy
Sharma, Meenakshi
Schwartz, Jason R
Yan, Jiabin
Sowers, Lawrence
Widger, William R
Fofanov, Yuriy
Vedeckis, Wayne V
Thompson, E Brad
author_sort Miller, Aaron L
collection PubMed
description BACKGROUND: Glucocorticoids (GCs) are often included in the therapy of lymphoid malignancies because they kill several types of malignant lymphoid cells. GCs activate the glucocorticoid receptor (GR), to regulate a complex genetic network, culminating in apoptosis. Normal lymphoblasts and many lymphoid malignancies are sensitive to GC-driven apoptosis. Resistance to GCs can be a significant clinical problem, however, and correlates with resistance to several other major chemotherapeutic agents. METHODS: We analyzed the effect of treatment with the cytosine analogue 5 aza-2’ deoxycytidine (AZA) on GC resistance in two acute lymphoblastic leukemia (T or pre-T ALL) cell lines- CEM and Molt-4- and a (B-cell) myeloma cell line, RPMI 8226. Methods employed included tissue culture, flow cytometry, and assays for clonogenicity, cytosine extension, immunochemical identification of proteins, and gene transactivation. High throughput DNA sequencing was used to confirm DNA methylation status. CONCLUSIONS: Treatment of these cells with AZA resulted in altered DNA methylation and restored GC-evoked apoptosis in all 3 cell lines. In CEM cells the altered epigenetic state resulted in site-specific phosphorylation of the GR, increased GR potency, and GC-driven induction of the GR from promoters that lie in CpG islands. In RPMI 8226 cells, expression of relevant coregulators of GR function was altered. Activation of p38 mitogen-activated protein kinase (MAPK), which is central to a feed-forward mechanism of site-specific GR phosphorylation and ultimately, apoptosis, occurred in all 3 cell lines. These data show that in certain malignant hematologic B- and T-cell types, epigenetically controlled GC resistance can be reversed by cell exposure to a compound that causes DNA demethylation. The results encourage studies of application to in vivo systems, looking towards eventual clinical applications.
format Online
Article
Text
id pubmed-4008436
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40084362014-05-03 Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells Miller, Aaron L Geng, Chuandong Golovko, Georgiy Sharma, Meenakshi Schwartz, Jason R Yan, Jiabin Sowers, Lawrence Widger, William R Fofanov, Yuriy Vedeckis, Wayne V Thompson, E Brad Cancer Cell Int Primary Research BACKGROUND: Glucocorticoids (GCs) are often included in the therapy of lymphoid malignancies because they kill several types of malignant lymphoid cells. GCs activate the glucocorticoid receptor (GR), to regulate a complex genetic network, culminating in apoptosis. Normal lymphoblasts and many lymphoid malignancies are sensitive to GC-driven apoptosis. Resistance to GCs can be a significant clinical problem, however, and correlates with resistance to several other major chemotherapeutic agents. METHODS: We analyzed the effect of treatment with the cytosine analogue 5 aza-2’ deoxycytidine (AZA) on GC resistance in two acute lymphoblastic leukemia (T or pre-T ALL) cell lines- CEM and Molt-4- and a (B-cell) myeloma cell line, RPMI 8226. Methods employed included tissue culture, flow cytometry, and assays for clonogenicity, cytosine extension, immunochemical identification of proteins, and gene transactivation. High throughput DNA sequencing was used to confirm DNA methylation status. CONCLUSIONS: Treatment of these cells with AZA resulted in altered DNA methylation and restored GC-evoked apoptosis in all 3 cell lines. In CEM cells the altered epigenetic state resulted in site-specific phosphorylation of the GR, increased GR potency, and GC-driven induction of the GR from promoters that lie in CpG islands. In RPMI 8226 cells, expression of relevant coregulators of GR function was altered. Activation of p38 mitogen-activated protein kinase (MAPK), which is central to a feed-forward mechanism of site-specific GR phosphorylation and ultimately, apoptosis, occurred in all 3 cell lines. These data show that in certain malignant hematologic B- and T-cell types, epigenetically controlled GC resistance can be reversed by cell exposure to a compound that causes DNA demethylation. The results encourage studies of application to in vivo systems, looking towards eventual clinical applications. BioMed Central 2014-04-23 /pmc/articles/PMC4008436/ /pubmed/24795534 http://dx.doi.org/10.1186/1475-2867-14-35 Text en Copyright © 2014 Miller et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Primary Research
Miller, Aaron L
Geng, Chuandong
Golovko, Georgiy
Sharma, Meenakshi
Schwartz, Jason R
Yan, Jiabin
Sowers, Lawrence
Widger, William R
Fofanov, Yuriy
Vedeckis, Wayne V
Thompson, E Brad
Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells
title Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells
title_full Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells
title_fullStr Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells
title_full_unstemmed Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells
title_short Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells
title_sort epigenetic alteration by dna-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008436/
https://www.ncbi.nlm.nih.gov/pubmed/24795534
http://dx.doi.org/10.1186/1475-2867-14-35
work_keys_str_mv AT milleraaronl epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells
AT gengchuandong epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells
AT golovkogeorgiy epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells
AT sharmameenakshi epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells
AT schwartzjasonr epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells
AT yanjiabin epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells
AT sowerslawrence epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells
AT widgerwilliamr epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells
AT fofanovyuriy epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells
AT vedeckiswaynev epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells
AT thompsonebrad epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells